Search

Your search keyword '"Rheumatoid arthritis -- Health aspects"' showing total 11 results
Start Over Descriptor "Rheumatoid arthritis -- Health aspects" Topic business
11 results on '"Rheumatoid arthritis -- Health aspects"'

1. TNF inhibitor cancer risk doubt

Subjects
Rheumatoid arthritis -- Risk factors, Rheumatoid arthritis -- Health aspects, Oncology, Experimental -- Health aspects, Cancer -- Risk factors, Cancer -- Health aspects, Cancer -- Research, Business, Business, international, Health care industry
Published
2006

2. Event Brief of Q3 2008 Roche Holding AG Sales Conference Call - Final

Subjects
Morgan Stanley -- Product introduction, Roche Holding AG -- Product introduction, Societe Generale S.A. -- Product introduction, Biological products industry -- Product introduction -- Health aspects, Rheumatoid factor -- Health aspects, Diabetes -- Health aspects, Banking industry -- Health aspects -- Product introduction, Erosion -- Health aspects, Customer relations -- Health aspects, Competition (Economics) -- Health aspects, Growth factors -- Health aspects, Pharmaceutical industry -- Product introduction -- Health aspects, Metastasis -- Health aspects, Stomach cancer -- Health aspects, Angiogenesis inhibitors -- Health aspects, Monoclonal antibodies -- Health aspects, Rheumatoid arthritis -- Health aspects, Workflow software, Banking industry, Business, Rituxan (Medication) -- Product introduction -- Health aspects, Tarceva (Medication) -- Product introduction -- Health aspects, Herceptin (Medication) -- Product introduction -- Health aspects, Avastin (Medication) -- Product introduction -- Health aspects
Abstract

PARTICIPANTS . Severin Schwan, Roche Holdings AG, CEO . Bill Burns, Roche Pharmaceuticals, CEO . Juergen Schwiezer, Roche Diagnostics, CEO . Erich Hunziker, Roche Group, CFO . Sachin Jain, Merrill [...]

Published
2008

4. Abbott to present wide range of investigational efficacy, safety and health outcomes data on Humira (adalimumab) at the Annual Meeting of the European League Against Rheumatism

Subjects
Rheumatoid arthritis -- Health aspects, Business, Chemicals, plastics and rubber industries, Humira (Medication) -- Health aspects
Abstract

Abbott scientists and independent researchers will highlight the latest investigational research findings on Humira (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6 Jun-9 Jun [...]

Published
2012

5. Alder Biopharmaceuticals to receive $15 M milestone payment from Bristol-Myers Squibb for initiation of Phase IIb clinical trial in rheumatoid arthritis of ALD518/BMS-945429 antibody therapeutic against IL-6

Subjects
Bristol-Myers Squibb Co. -- Product development, Biopharmaceutics -- Product development -- Health aspects, Rheumatoid factor -- Health aspects, Clinical trials -- Health aspects, Interleukins -- Product development -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Business, Chemicals, plastics and rubber industries
Abstract

Alder Biopharmaceuticals Inc announced it will receive a $15 M milestone payment from Bristol-Myers Squibb for the initiation of a Phase IIb clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an [...]

Published
2011

6. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6

Subjects
Bristol-Myers Squibb Co. -- Product development, Biopharmaceutics -- Product development -- Health aspects, Rheumatoid factor -- Health aspects, Clinical trials -- Health aspects, Interleukins -- Product development -- Health aspects, Rheumatoid arthritis -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Business, News, opinion and commentary
Abstract

BOTHELL, Wash., June 20, 2011 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b [...]

Published
2011

7. Compugen announces positive therapeutic effect of CGEN-15001 in animal model of rheumatoid arthritis

Subjects
Compugen Ltd., Rheumatoid factor -- Health aspects, Biotechnology industry -- Health aspects, Antirheumatic agents -- Health aspects, Rheumatoid arthritis -- Health aspects, Business, Chemicals, plastics and rubber industries
Abstract

Compugen Ltd announced that administration of CGEN-15001 in an animal model of rheumatoid arthritis (RA) dramatically ameliorates the clinical symptoms of the disease. These results, combined with earlier results in [...]

Published
2010

8. Analyse Therapeutic Clinical Intelligence - Rheumatoid Arthritis

Subjects
Rheumatoid factor -- Health aspects, Biological products -- Market research -- Health aspects, Rheumatoid arthritis -- Health aspects, Marketing research, Business, Business, international
Abstract

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c78644) has announced the addition of 'Therapeutic Clinical Intelligence - Rheumatoid Arthritis' to their offering. The world-wide market for Rheumatoid Arthritis (RA) therapeutics has [...]

Published
2008

9. Chelsea Therapeutics Closes $21.5 Million Placement with Leading Biotech Investors; Proceeds Enable Phase II Proof of Concept Studies of CH-1504 in Rheumatoid Arthritis and Psoriasis and Expansion of Therapeutic Pipeline

Subjects
Biotechnology -- Health aspects, Rheumatoid arthritis -- Health aspects, Psoriasis -- Health aspects, Drugs -- Health aspects, Business, Business, international
Abstract

CHARLOTTE, N.C. -- Chelsea Therapeutics International, Ltd. (OTCBB: CHTP), completed a private placement of approximately 7.2 million shares of its common stock to institutional and other accredited investors, resulting in [...]

Published
2006

10. From the South Seas, bliss

Author

Handscomb, Mark

Subjects
Corals -- Health aspects, Rheumatoid arthritis -- Health aspects, Bones -- Health aspects, Business, Business, international, Retail industry
Abstract

Rheumatoid arthritis can be treated with three species of coral from New Caledonia in the south Pacific. Coral wedges fuse joints, straighten bent limbs and replace shattered bones. Coral, the external skeleton of a marine animal, has a similar structure to bone. In these operations, human blood vessels invade the holes in coral and new bone forms. Eventually the coral disappears.

Published
1993

11. Abmaxis Inc., of Santa Clara, Calif., and MaimoniDex RA Ltd., of Jerusalem, signed an agreement to jointly develop a therapeutic human monoclonal antibody for the treatment of rheumatoid arthritis and other inflammatory diseases

Subjects
Monoclonal antibodies -- Health aspects, Biopharmaceutics -- Product development, Biopharmaceutics -- Health aspects, Drug therapy -- Health aspects, Rheumatoid arthritis -- Drug therapy, Rheumatoid arthritis -- Health aspects, Biotechnology industry, Business, Business, international
Abstract

Abmaxis Inc., of Santa Clara, Calif., and MaimoniDex RA Ltd., of Jerusalem, signed an agreement to jointly develop a therapeutic human monoclonal antibody for the treatment of rheumatoid arthritis and [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results